BioInvent International AB (publ)'s latest marketcap:
As of 08/13/2025, BioInvent International AB (publ)'s market capitalization has reached $256.21 M. According to our data, BioInvent International AB (publ) is the 18952th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | $256.21 M |
| Revenue (ttm) | $6.36 M |
| Net Income (ttm) | $-48,982,695.7 |
| Shares Out | 0 |
| EPS (ttm) | $-0.75 |
| Forward PE | 24.78 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/26/2025 |
BioInvent International AB (publ)'s yearly market capitalization.
| Date | Market Cap(£) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/13/2025 | £188.78 M | $256.21 M | 2.99% | 18952 |
| 12/30/2024 | £183.3 M | $229.32 M | 88.74% | 18144 |
| 12/29/2023 | £97.12 M | $123.63 M | -41.42% | 21696 |
| 12/30/2022 | £165.78 M | $200.49 M | -25.08% | 18011 |
| 12/30/2021 | £221.27 M | $299.1 M | 40.59% | 16485 |
| 12/30/2020 | £157.38 M | $215.14 M | 214.27% | 16381 |
| 12/30/2019 | £50.08 M | $66.4 M | -14.59% | 20297 |
| 12/28/2018 | £58.63 M | $74.75 M | 2.85% | 18816 |
| 12/29/2017 | £57.01 M | $76.96 M | -31.7% | 19319 |
| 12/30/2016 | £83.46 M | $103.04 M | 69.15% | 15823 |
Company Profile
About BioInvent International AB (publ)
BioInvent International AB (publ) is a clinical-stage biotech company focused on discovering, researching, and developing novel immuno-modulatory antibodies for cancer treatment. Headquartered in Lund, Sweden, the company operates across Europe, the United States, and internationally.
Key Drug Candidates
- BI-1808 – Phase 2 clinical trial for solid tumors targeting Tumor Necrosis Factor Receptor-2 (TNFR2).
- BI-1910 – Phase 1 clinical trial for solid tumors targeting TNFR2.
- BI-1206/rituximab – Phase 2 clinical trial for non-Hodgkin’s lymphoma.
- BI-1206/pembrolizumab & BI-1607/trastuzumab – Phase 1 clinical trial for solid tumors targeting FCYRIIB.
- BT-001 – Phase 1 clinical trial for solid tumors targeting Cytotoxic T Lymphocyte-Associated Protein-4.
Strategic Partnerships
- Collaboration with Transgene to develop BT-001 oncolytic viruses for solid tumors.
- Partnership with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda.
- Licensing agreement with CASI Pharmaceuticals for BI-1206.
Founded in 1996, BioInvent continues to advance innovative therapies in immuno-oncology.
Frequently Asked Questions
-
What is BioInvent International AB (publ)'s (LON-0H22) current market cap?As of 08/13/2025, BioInvent International AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $256.21 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does BioInvent International AB (publ) (LON-0H22) rank globally by market cap?BioInvent International AB (publ) global market capitalization ranking is approximately 18952 as of 08/13/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.